Champlain Investment Partners LLC Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Champlain Investment Partners LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, Holdings Channel reports. The fund bought 1,099,885 shares of the medical equipment provider’s stock, valued at approximately $79,291,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC increased its stake in shares of Hologic by 8.1% in the fourth quarter. Insigneo Advisory Services LLC now owns 6,061 shares of the medical equipment provider’s stock worth $437,000 after purchasing an additional 454 shares in the last quarter. Main Street Financial Solutions LLC raised its holdings in Hologic by 8.7% during the fourth quarter. Main Street Financial Solutions LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $289,000 after acquiring an additional 321 shares during the period. Ontario Teachers Pension Plan Board raised its holdings in Hologic by 77.3% during the fourth quarter. Ontario Teachers Pension Plan Board now owns 38,366 shares of the medical equipment provider’s stock valued at $2,766,000 after acquiring an additional 16,729 shares during the period. Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of Hologic in the fourth quarter valued at about $734,000. Finally, Canada Post Corp Registered Pension Plan bought a new position in shares of Hologic in the fourth quarter worth about $234,000. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Finally, Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Down 2.4 %

Shares of HOLX opened at $56.50 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average of $61.87 and a 200 day moving average of $71.15. The company has a market cap of $12.68 billion, a PE ratio of 17.82, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 52-week low of $56.05 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.